[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f7U5g_QkDXBifBQtDgFIPbV88Dr-EO8N-88mG3XZlh7o":8,"$fSvmPp9nZCBwYnmjiscyT1YVUcKGGaL_YdQVsh1c-uCU":56,"$fVHaTGLHR-xJfhhL7IEEREPJcqafq0Krif8mtf536Hr0":60},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":55},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":29,"seoKeywords":30,"seoDescription":31,"shelvesTime":32,"version":33,"menus":34,"menuId":36,"type":43,"quality":54,"commentCount":21,"isComment":43},57957,867187,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","刘艳","辛集市第二医院","肿瘤科","主治医师",33,0,"贝伐珠单抗与卡培他滨安全用药全指南——关注细节，疗效升级","","https://ystcdn.venuertc.com/venue/AI/e7f79a9f-1477-44cd-8a1e-5e9e7828efa0.jpg","\u003Cdiv class=\"drug-guide-container\">\n  \u003Ch2 id=\"material_title\" class=\"drug-guide-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">贝伐珠单抗与卡培他滨安全用药全指南——关注细节，疗效升级\u003C/h2>\n  \n  \u003Csection class=\"drug-intro-section drug-bg-1\">\n    \u003Cdiv class=\"drug-intro-block\">\n      \u003Cp>说起靶向药和口服化疗药物，贝伐珠单抗和卡培他滨的组合常出现在肿瘤治疗方案中。靶向和化疗，一个静脉用药、一个口服药片，各自有鲜明的特点。想要用好这两种药，关键细节还真不少：包括服用方法、常见反应、特殊群体的注意事项，以及药物相互作用等。今天，我们就来系统聊聊使用贝伐珠单抗和卡培他滨时，必须关注的\u003Cstrong>7个关键环节\u003C/strong>。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-2\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 药品成分与剂型亮点\u003C/h2>\n    \u003Cul class=\"drug-list\">\n      \u003Cli>\u003Cstrong>贝伐珠单抗（Bevacizumab）：\u003C/strong>是一类重组人源化单克隆抗体，作用于血管内皮生长因子（VEGF）。常见剂型为静脉注射液，需在医院严格操作。\u003C/li>\n      \u003Cli>\u003Cstrong>卡培他滨（Capecitabine）：\u003C/strong>为口服氟嘧啶类抗肿瘤药，是一种片剂。进入体内后转化为活性药物，对肿瘤细胞具有杀伤作用。常用规格有0.5g和1.0g。\u003C/li>\n      \u003Cli>两者常联合用于肿瘤的维持治疗和联合治疗方案中，对提高治疗依从性有积极作用。\u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-3\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 药理作用机制——各司其职\u003C/h2>\n    \u003Cdiv class=\"drug-info-block\">\n      \u003Cul>\n        \u003Cli>\u003Cspan class=\"drug-emoji\">🧬\u003C/span> \u003Cstrong>贝伐珠单抗：\u003C/strong>通过结合VEGF，阻断新生血管生成，从源头抑制肿瘤生长所需的养分和氧气供应。\u003C/li>\n        \u003Cli>\u003Cspan class=\"drug-emoji\">💊\u003C/span> \u003Cstrong>卡培他滨：\u003C/strong>属于抗代谢药，口服后依次在肝脏和肿瘤组织内转化为5-氟尿嘧啶（5-FU），有效阻断肿瘤细胞分裂。\u003C/li>\n      \u003C/ul>\n      \u003Cp>两药联用，实现“断水断粮”配合“定点打击”，提升抗肿瘤活性。\u003C/p>\n      \u003Cp class=\"drug-reference\">参考文献: Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350(23), 2335-2342.\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-4\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 正确用法用量——精准投药，效果保障\u003C/h2>\n    \u003Cdiv class=\"drug-info-block\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>贝伐珠单抗：\u003C/strong>只可静脉滴注，必须在专业医院由医务人员操作。滴注时间一般在90分钟以上，严禁肌注或皮下注射。首次用药需密切观察不良反应。\u003C/li>\n        \u003Cli>\u003Cstrong>卡培他滨：\u003C/strong>口服用药，建议在餐后30分钟内整片吞服，勿嚼碎、粉碎或溶解。用1杯温水送服，保持剂量准确。\u003C/li>\n        \u003Cli>标准剂量需严格参照医师处方执行。常见周期是连续服药14天，停药7天为一个周期。\u003C/li>\n      \u003C/ul>\n      \u003Cp>有患者出现恶心时，医生通常会搭配止吐药物。出现异物感或吞咽困难时，应及时报告医师调整给药。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-5\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 特殊人群如何用药？\u003C/h2>\n    \u003Cdiv class=\"drug-info-block\">\n      \u003Cul>\n        \u003Cli>\u003Cspan class=\"drug-emoji\">👵\u003C/span> \u003Cstrong>老年患者：\u003C/strong>肝肾功能下降时，卡培他滨需调整剂量。乙肝、肾功能异常者，贝伐珠单抗需严格风险评估。\u003C/li>\n        \u003Cli>\u003Cstrong>肝肾功能不全：\u003C/strong>肾功能不全（如肌酐升高者），卡培他滨应减量或停用。肝功能损伤者用药须个体化。\u003C/li>\n        \u003Cli>\u003Cstrong>孕妇与哺乳期女性：\u003C/strong>两药均有致畸与生殖毒性风险，孕妇、哺乳妇女禁用。\u003C/li>\n        \u003Cli>\u003Cstrong>儿童：\u003C/strong>目前无充分安全性数据，不推荐儿童使用。\u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"drug-case\">临床中曾有位肾功能受损老年患者，医生及时调整卡培他滨剂量，有效降低了药物不良反应风险。\u003C/p>\n      \u003Cp class=\"drug-reference\">资料来源: Hoff, P. M., Ansari, R., Batist, G., et al. (2001). Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer. Journal of Clinical Oncology, 19(8), 2282-2292.\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-6\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 常见不良反应及应对办法\u003C/h2>\n    \u003Cdiv class=\"drug-info-block\">\n      \u003Cul>\n        \u003Cli>\u003Cspan class=\"drug-emoji\">🤒\u003C/span> \u003Cstrong>卡培他滨：\u003C/strong>可见手足红肿、皮疹、口腔溃疡、腹泻、食欲减退。部分患者有肝酶升高。\u003C/li>\n        \u003Cli>\u003Cstrong>贝伐珠单抗：\u003C/strong>可能引起高血压、蛋白尿、出血倾向、伤口愈合变慢，极少见肠穿孔及严重过敏反应。\u003C/li>\n        \u003Cli>药物说明书数据表明，手足综合征（红肿、疼痛）发生率约为17%，高血压发生率约6-10%。\u003C/li>\n        \u003Cli>正确做法：出现手足脱皮、红肿时及时保湿，避免摩擦。如有严重腹泻、高烧或异常出血，立即通知医生。贝伐珠单抗用药期间要定期量血压和尿常规。\u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"drug-case\">有一例患者服用卡培他滨后出现轻度肝功能异常，按时监测并及时调整用药，未见进展。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-1\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 药物相互作用你不可忽视\u003C/h2>\n    \u003Cdiv class=\"drug-info-block\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>卡培他滨：\u003C/strong>与华法林（抗凝药）、苯妥英、氨基糖苷类抗生素等药物有相互作用，易加重出血风险或药物毒性。与抗酸药同服可能影响吸收。避免同时服用含铁和钙的补充剂。\u003C/li>\n        \u003Cli>\u003Cstrong>贝伐珠单抗：\u003C/strong>与含白蛋白药物、溶栓药物、其它抗肿瘤药物联合时需评估毒副作用的叠加。\u003C/li>\n        \u003Cli>饮酒会加重肝脏负担，并可能增加不良反应风险。\u003C/li>\n        \u003Cli>同时服用其他降压药、利尿剂、口服抗凝剂等，需征求医生建议，尽量避免自行加药。\u003C/li>\n      \u003C/ul>\n      \u003Cp>正确做法：如需加用其他药物务必提前告知医生并做好药物记录。\u003C/p>\n      \u003Cp class=\"drug-reference\">参考：Saif, M. W., & Choma, A. (2009). Bevacizumab and risk of gastrointestinal perforation. The Lancet Oncology, 10(6), 559-567.\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-2\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存方法、漏服与过量应对\u003C/h2>\n    \u003Cdiv class=\"drug-info-block\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>贝伐珠单抗：\u003C/strong>保存于2～8℃冰箱内，避免冷冻、不要暴露于强光。开瓶后建议尽快用完。\u003C/li>\n        \u003Cli>\u003Cstrong>卡培他滨：\u003C/strong>需避光、干燥处密封保存，室温即可。药品远离儿童，避免误服。\u003C/li>\n        \u003Cli>\u003Cspan class=\"drug-emoji\">⏰\u003C/span> \u003Cstrong>漏服处理：\u003C/strong>如忘记服用卡培他滨，不应补服漏掉剂量，只需按原计划下次准时服用即可。切忌一次服用两倍剂量。\u003C/li>\n        \u003Cli>\u003Cspan class=\"drug-emoji\">⚠️\u003C/span> \u003Cstrong>过量处理：\u003C/strong>一旦过量服用或误用，注意记录用药时间与剂量，第一时间就医处理，必要时采取洗胃、对症支持治疗。\u003C/li>\n        \u003Cli>过期药品请送交专业药物回收点，不要自行随意丢弃。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-3\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 用药监测与就医时机\u003C/h2>\n    \u003Cdiv class=\"drug-info-block\">\n      \u003Cul>\n        \u003Cli>用药期间需定期监测血常规、肝肾功能。建议每周检测一次，确保用药安全。\u003C/li>\n        \u003Cli>出现持续发热、严重腹泻、出血、呼吸困难等异常反应，应立即停药并就医。\u003C/li>\n        \u003Cli>所有随访记录、化验单、用药历程建议归档保留，以便随时与临床医生沟通。\u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"drug-case\">病例提示：一位患者定期检测血象、酶谱，实现异常信号早发现，安全度过维持治疗期。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-4\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 真实用药案例分享\u003C/h2>\n    \u003Cdiv class=\"drug-info-block\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>案例一：\u003C/strong>60岁女性，口服卡培他滨（1.0g bid d1-14，21天一周期）配合贝伐珠单抗维持，定期监测血象与肝肾功能，未见严重副作用。\u003C/li>\n        \u003Cli>\u003Cstrong>案例二：\u003C/strong>曾有老年患者卡培他滨引起手足症状，暂停1周期后症状缓解，再循序减量恢复治疗。\u003C/li>\n      \u003C/ul>\n      \u003Cp>案例仅演示用药过程，不涉及患者病情。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-5\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 常见用药疑问解答\u003C/h2>\n    \u003Cdiv class=\"drug-info-block\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>Q: 可以自行停药或加药吗？\u003C/strong>\u003Cbr>\n        A: 不建议，擅自调整方案有风险。需遵循医嘱，提升安全系数。\u003C/li>\n        \u003Cli>\u003Cstrong>Q: 剂量出现疑问怎么办？\u003C/strong>\u003Cbr>\n        A: 及时与医生和药师沟通，记录每日服药剂量，不要凭感觉更改用量。\u003C/li>\n        \u003Cli>\u003Cstrong>Q: 更换品牌对疗效有影响吗？\u003C/strong>\u003Cbr>\n        A: 建议连续使用同一厂家，若需更换需告知医生，有些不同品牌的剂型和辅料可能不同。\u003C/li>\n        \u003Cli>\u003Cstrong>Q: 如何改善口服药不良反应？\u003C/strong>\u003Cbr>\n        A: 足量饮水、合理润肤、轻度手足症状可使用护肤品；如不适持续，加快就医，提高用药安全。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drug-section drug-bg-summary\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语：用好每一粒药，避免每一次风险\u003C/h2>\n    \u003Cdiv class=\"drug-summary-block\">\n      \u003Cp>贝伐珠单抗和卡培他滨联用，是抗肿瘤药物中的重要组合。严格遵医嘱，重视每一次剂量调整、每一项化验监测、每一次不良反应反馈，就是把主动权握在了自己手中。\u003Cspan class=\"drug-emoji\">🛡️\u003C/span>合理用药、拒绝盲目，是提升疗效和降风险的共同法宝。遇到用药疑问时，积极与医生和药师联系，是您安全保障的坚实后盾。\u003C/p>\n    \u003C/div>\n    \u003Cdiv class=\"drug-ref-summary\">\n      \u003Ch3 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">核心参考文献\u003C/h3>\n      \u003Cul>\n        \u003Cli>Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 350(23), 2335-2342.\u003C/li>\n        \u003Cli>Hoff, P. M., Ansari, R., Batist, G., et al. (2001). Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer. \u003Cem>Journal of Clinical Oncology\u003C/em>, 19(8), 2282-2292.\u003C/li>\n        \u003Cli>Saif, M. W., & Choma, A. (2009). Bevacizumab and risk of gastrointestinal perforation. \u003Cem>The Lancet Oncology\u003C/em>, 10(6), 559-567.\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n/* 独立作用于本页面的全局样式，避免与外部页面冲突 */\n.drug-guide-container {\n  max-width: 850px;\n  margin: 36px auto 50px auto;\n  background: #fff;\n  border-radius: 18px;\n  box-shadow: 0 4px 24px rgba(60, 60, 60, 0.13);\n  padding: 24px 30px 40px 30px;\n  font-family: \"PingFang SC\", \"Microsoft YaHei\", Arial, sans-serif;\n  letter-spacing: 0.02em;\n  line-height: 1.8;\n}\n.drug-guide-title {\n  font-size: 2.1em;\n  color: #174056;\n  font-weight: 700;\n  margin-bottom: 18px;\n  text-align: center;\n}\n.drug-section {\n  margin-bottom: 30px;\n  border-radius: 14px;\n  padding-top: 2px;\n  padding-bottom: 10px;\n  background: #fcfcfc;\n}\n.drug-section-title {\n  font-size: 1.28em;\n  color: #24698c;\n  font-weight: bold;\n  padding: 14px 0 10px 16px;\n  border-left: 5px solid #4eaeda;\n  background: linear-gradient(90deg, #e4f4fa 40%, #f9fafb 90%);\n  margin-bottom: 0.5em;\n  border-radius: 8px 8px 0 0;\n}\n.drug-bg-1 {\n  background: linear-gradient(110deg, #f3f6fa 70%, #f7fbfd 100%);\n}\n.drug-bg-2 {\n  background: linear-gradient(105deg, #f7faf3 70%, #f4fafb 100%);\n}\n.drug-bg-3 {\n  background: linear-gradient(105deg, #f8f6fb 70%, #f4f7fa 100%);\n}\n.drug-bg-4 {\n  background: linear-gradient(105deg, #fdf6f4 70%, #fbf9f7 100%);\n}\n.drug-bg-5 {\n  background: linear-gradient(95deg, #f6f7fd 70%, #f4fafe 100%);\n}\n.drug-bg-6 {\n  background: linear-gradient(100deg, #f8fbf4 70%, #f8fafc 100%);\n}\n.drug-bg-summary {\n  background: linear-gradient(96deg, #f2fbf7 82%, #f5f6f9 100%);\n  margin-bottom: 0;\n}\n\n.drug-intro-block,\n.drug-info-block,\n.drug-summary-block {\n  padding: 12px 20px 8px 16px;\n  font-size: 1.05em;\n}\n\n.drug-list {\n  padding-left: 34px;\n  margin-top: 0.7em;\n  margin-bottom: 0.3em;\n}\n.drug-list li {\n  margin-bottom: 7px;\n  list-style: disc inside;\n}\n\n.drug-info-block ul {\n  list-style: disc inside;\n  margin-left: 28px;\n  margin-bottom: 7px;\n  margin-top: 0.5em;\n}\n.drug-info-block li {\n  margin-bottom: 6px;\n}\n\n.drug-emoji {\n  font-size: 1.18em;\n  margin-right: 2px;\n  vertical-align: middle;\n}\n\n.drug-reference, .drug-ref-summary {\n  font-size: 0.98em;\n  color: #75858f;\n  margin-top: 8px;\n  line-height: 1.6;\n}\n.drug-case {\n  color: #766a4f;\n  background: #faf3e6;\n  padding: 8px 12px;\n  border-left: 3px solid #dcb57b;\n  border-radius: 5px;\n  margin-bottom: 7px;\n  margin-top: 5px;\n}\n\n.drug-ref-summary h3 {\n  margin-bottom: 6px;\n  font-size: 1.06em;\n  color: #348bb0;\n  font-weight: bold;\n}\n.drug-ref-summary ul {\n  margin-left: 22px;\n  margin-bottom: 1em;\n}\n.drug-ref-summary li {\n  margin-bottom: 4px;\n  font-size: 0.98em;\n}\n\n@media (max-width: 600px) {\n  .drug-guide-container {\n    padding: 8px 4px 18px 4px;\n    margin: 6px;\n    font-size: 0.98em;\n  }\n  .drug-guide-title {\n    font-size: 1.19em;\n    padding-bottom: 2px;\n  }\n  .drug-section-title {\n    font-size: 1em;\n    padding-left: 8px;\n  }\n  .drug-info-block, .drug-intro-block, .drug-summary-block {\n    padding: 7px 4px 4px 8px;\n    font-size: 0.92em; \n  }\n  .drug-list, .drug-info-block ul, .drug-ref-summary ul {\n    margin-left: 10px;\n    font-size: 0.96em;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"drug-guide-container\">\n  \u003Ch2 id=\"material_title\" class=\"drug-guide-title\" style=\"color: ",524,"2025-08-11 10:23:35","贝伐珠单抗与卡培他滨安全用药指南：细节优化与疗效提升  \n","贝伐珠单抗,卡培他滨,安全用药指南,联合用药方案,肿瘤治疗,副作用管理,剂量调整,疗效优化  \n","本指南详细解析贝伐珠单抗与卡培他滨的联合用药规范，涵盖剂量选择、不良反应监测、疗效提升策略及临床注意事项，帮助医疗从业者实现精准治疗与患者安全管理。","2025-08-17 14:14:00",2,[35],{"menuId":36,"menuName":37,"parentId":21,"orderNum":33,"path":38,"component":39,"isFrame":40,"isCache":41,"menuType":42,"visible":43,"status":21,"createDept":6,"remark":23,"createTime":44,"children":45,"columnImage":46,"columnLogo":47,"uncheckedLogo":6,"checkedLogo":6,"isHot":43,"isHome":21,"forceLogin":21,"color":48,"seoTitle":49,"seoKeywords":50,"seoDescription":51,"contentNum":6,"promotionalPoster":52,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":53,"routerPath":38,"componentInfo":39},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":57,"success":55},{"pageNo":43,"pageSize":58,"result":59,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":61,"success":55},{"authors":62,"appraiseDimensionScoresVos":63},[],[]]